References
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021; 71: 7–33. doi: 10.3322/caac.21654
- Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144: 1941–53. doi: 10.1002/ijc.31937
- Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 339–57. doi: 10.1016/j.annonc.2022.12.009
- Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 358–76. doi: 10.1016/j.annonc.2022.12.013
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108. doi: 10.3322/caac.21262
- Murray PV, O’Brien ME, Sayer R, Cooke N, Knowles G, Miller AC, et al. The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway. Lung Cancer 2003; 42: 283–90. doi: 10.1016/s0169-5002(03)00358-1
- Copeland J, Neal E, Phillips W, Hofferberth S, Lathan C, Donington J, et al. Restructuring lung cancer care to accelerate diagnosis and treatment in patients vulnerable to healthcare disparities using an innovative care model. MethodsX 2023; 11: 102338. doi: 10.1016/j.mex.2023.102338
- Dunn J, Garvey G, Valery PC, Ball D, Fong KM, Vinod S, et al. Barriers to lung cancer care: health professionals’ perspectives. Support Care Cancer 2017; 25: 497–504. doi: 10.1007/s00520-016-3428-3
- Kutubudin F, Robinson R, Deus P, Hughes K, Wight AG. Impact of national optimal lung cancer pathway – can we meet the 28 day standard by 2020? [abstract]. Thorax 2018; 73(Suppl 4): A140. doi: 10.1136/thorax-2018-212555.229
- Jaly A, Conroy S, Mohsin N. Implementing the National Optimal Lung Cancer Pathway; STHK experience. European Congress of Radiology - ECR 2020; Poster: C-12308. [Internet]. Available at:
https://dx.doi.org/10.26044/ecr2020/C-12308 . doi: 10.26044/ecr2020/C-12308 - Fung-Kee-Fung M, Maziak DE, Pantarotto JR, Smylie J, Taylor L, Timlin T, et al. Regional process redesign of lung cancer care: a learning health system pilot project. Curr Oncol 2018; 25: 59–66. doi: 10.3747/co.25.3719
- Jacobsen MM, Silverstein SC, Quinn M, Waterston LB, Thomas CA, Benneyan JC, et al. Timeliness of access to lung cancer diagnosis and treatment: a scoping literature review. Lung Cancer 2017; 112: 156–64. doi: 10.1016/j.lungcan.2017.08.011
- Rankin NM, York S, Stone E, Barnes D, McGregor D, Lai M, et al. Pathways to lung cancer diagnosis: a qualitative study of patients and general practitioners about diagnostic and pretreatment intervals. Ann Am Thorac Soc 2017; 14: 742–53. doi: 10.1513/AnnalsATS.201610-817OC
- Ost DE, Yeung SCJ, Tanoue LT, Gould MK. Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(5 Suppl): e121S–41S. doi: 10.1378/chest.12-2352
- Kanashiki M, Satoh H, Ishikawa H, Yamashita YT, Ohtsuka M, Sekizawa K. Time from finding abnormality on mass-screening to final diagnosis of lung cancer. Oncol Rep 2003; 10: 649–52. doi: 10.3892/or.10.3.649
- Kashiwabara K, Koshi S, Itonaga K, Nakahara O, Tanaka M, Toyonaga M. Outcome in patients with lung cancer found on lung cancer mass screening roentgenograms, but who did not subsequently consult a doctor. Lung Cancer 2003; 40: 67–72. doi: 10.1016/s0169-5002(02)00505-6
- Salomaa ER, Sallinen S, Hiekkanen H, Liippo K. Delays in the diagnosis and treatment of lung cancer. Chest 2005; 128: 2282–8. doi: 10.1378/chest.128.4.2282
- Saint-Jacques N, Rayson D, Al-Fayea T, Virik K, Morzycki W, Younis T. Waiting times in early-stage non-small cell lung cancer (NSCLC). J Thorac Oncol 2008; 3: 865–70. doi: 10.1097/JTO.0b013e318180210c
- Risberg T, Sorbye SW, Norum J, Wist EA. Diagnostic delay causes more psychological distress in female than in male cancer patients. Anticancer Res 1996; 16: 995–9. PMID: 8687166.
- Malalasekera A, Nahm S, Blinman PL, Kao SC, Dhillon HM, Vardy JL. How long is too long? A scoping review of health system delays in lung cancer. Eur Respir Rev 2018; 27: 180045. doi: 10.1183/16000617.0045-2018
- Neal RD, Robbe IJ, Lewis M, Williamson I, Hanson J. The complexity and difficulty of diagnosing lung cancer: findings from a national primary-care study in Wales. Prim Health Care Res Dev 2015; 16: 436–49. doi: 10.1017/S1463423614000516
- Al Achkar M, Zigman Suchsland M, Walter FM, Neal RD, Goulart BHL, Thompson MJ. Experiences along the diagnostic pathway for patients with advanced lung cancer in the USA: a qualitative study. BMJ Open 2021; 11: e045056. doi: 10.1136/bmjopen-2020-045056
- White V, Bergin RJ, Thomas RJ, Whitfield K, Weller D. The pathway to diagnosis and treatment for surgically managed lung cancer patients. Fam Pract 2020; 37: 234–41. doi: 10.1093/fampra/cmz064.z
- Dunican E, Uzbeck M, Clince J, Toner S, Royston D, Logan MP, et al. Outcomes of patients presenting to a dedicated rapid access lung cancer clinic. Ir Med J 2011; 104: 265–8. PMID: 22132593
- Aasebo U, Strom HH, Postmyr M. The Lean method as a clinical pathway facilitator in patients with lung cancer. Clin Respir J 2012; 6:169–74. doi: 10.1111/j.1752-699X.2011.00271.x
- Hueto Pérez De Heredia J, Cebollero Rivas P, Cascante Rodrigo JA, Andrade Vela I, Pascal Martínez I, Boldú Mitjans J, et al. Evaluation of the use of a rapid diagnostic consultation of lung cancer. Delay time of diagnosis and therapy. Arch Bronconeumol 2012; 48: 267–73. doi: 10.1016/j.arbr.2012.06.003
- Lo DS, Zeldin RA, Skrastins R, Fraser IM, Newman H, Monavvari A, et al. Time to treat: a system redesign focusing on decreasing the time from suspicion of lung cancer to diagnosis. J Thorac Oncol 2007; 2: 1001–6. doi: 10.1097/JTO.0b013e318158d4b6
- Murphy DR, Wu L, Thomas EJ, Forjuoh SN, Meyer AN, Singh H. Electronic trigger-based intervention to reduce delays in diagnostic evaluation for cancer: a cluster randomized controlled trial. J Clin Oncol 2015; 33: 3560–7. doi: 10.1200/JCO.2015.61.1301
- Triller N, Bereš V, Rozman A. [Delays in the diagnosis and treatment of lung cancer: can the period between the onset of symptoms and the diagnosis and treatment be shortened?] [Slovenian]. [Internet]. Zdrav Vestn 2010; 79: 618–22. [cited 2020 Jan 10]. Available from:
https://vestnik.szd.si/index.php/ZdravVest/article/view/287 - Aapro M, Bossi P, Dasari A, Fallowfield L, Gascon P, Geller M, et al. Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. Support Care Cancer 2020; 28: 4589–12. doi: 10.1007/s00520-020-05539-1